Literature DB >> 15042359

Randomized controlled trial of screening for hepatocellular carcinoma.

Bo-Heng Zhang1, Bing-Hui Yang, Zhao-You Tang.   

Abstract

PURPOSE: Screening for hepatocellular carcinoma (HCC) has been conducted for over 20 years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.
METHODS: This study included 18,816 people, aged 35-59 years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6 months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.
RESULTS: The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41-0.98).
CONCLUSIONS: Our finding indicated that biannual screening reduced HCC mortality by 37%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042359     DOI: 10.1007/s00432-004-0552-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Prospective study of early detection for primary liver cancer.

Authors:  B Yang; B Zhang; Y Xu; W Wang; Y Shen; A Zhang; Z Xu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  [DETECTION OF EMBRYO-SPECIFIC ALPHA-GLOBULIN IN THE BLOOD SERUM OF A PATIENT WITH PRIMARY LIVER CANCER].

Authors:  Iu S TATARINOV
Journal:  Vopr Med Khim       Date:  1964 Jan-Feb

Review 4.  Workshop on screening for hepatocellular carcinoma.

Authors:  B J McMahon; T London
Journal:  J Natl Cancer Inst       Date:  1991-07-03       Impact factor: 13.506

5.  Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis.

Authors:  F Izzo; F Cremona; F Ruffolo; R Palaia; V Parisi; S A Curley
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

6.  Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.

Authors:  B Zhang; B Yang
Journal:  J Med Screen       Date:  1999       Impact factor: 2.136

7.  Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.

Authors: 
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

8.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.

Authors:  B J McMahon; L Bulkow; A Harpster; M Snowball; A Lanier; F Sacco; E Dunaway; J Williams
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

9.  Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population.

Authors:  M Sherman; K M Peltekian; C Lee
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

10.  Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan.

Authors:  S Mima; C Sekiya; H Kanagawa; H Kohyama; K Gotoh; H Mizuo; M Ijiri; T Tanabe; N Maeda; K Okuda
Journal:  J Gastroenterol Hepatol       Date:  1994 Jul-Aug       Impact factor: 4.029

View more
  405 in total

1.  Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

Authors:  Federico Piñero; Fernando Rubinstein; Sebastián Marciano; Nora Fernández; Jorge Silva; Yanina Zambelo; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Carlos Miguez; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

2.  Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.

Authors:  Mauro Borzio; Elena Dionigi; Angelo Rossini; Anna Toldi; Giampiero Francica; Fabio Fornari; Andrea Salmi; Fabio Farinati; Susanna Vicari; Massimo Marignani; Fulvia Terracciano; Barbara Ginanni; Rodolfo Sacco
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

3.  Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma.

Authors:  Denise M Harnois
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

4.  The role of serum biomarkers in hepatocellular carcinoma surveillance.

Authors:  Jorge A Marrero; Keith S Henley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

5.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

6.  Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Authors:  Ashil J Gosalia; Paul Martin; Patricia D Jones
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

7.  Screening for hepatocellular carcinoma by Egyptian physicians.

Authors:  Sahar M Hassany; Ehab F Abdou Moustafa; Mohamed El Taher; Afaf Adel Abdeltwab; Hubert E Blum
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

8.  Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis.

Authors:  Hajime Aino; Shuji Sumie; Takashi Niizeki; Ryoko Kuromatsu; Nobuyoshi Tajiri; Masahito Nakano; Manabu Satani; Shingo Yamada; Shusuke Okamura; Shigeo Shimose; Hiroaki Sumie; Takuji Torimura; Michio Sata
Journal:  Mol Clin Oncol       Date:  2014-02-14

Review 9.  Quality improvement in gastroenterology clinical practice.

Authors:  Rakhi Kheraj; Sumeet K Tewani; Gyanprakash Ketwaroo; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

Review 10.  Role of US LI-RADS in the LI-RADS Algorithm.

Authors:  Shuchi K Rodgers; David T Fetzer; Helena Gabriel; James H Seow; Hailey H Choi; Katherine E Maturen; Ashish P Wasnik; Tara A Morgan; Nirvikar Dahiya; Mary K O'Boyle; Yuko Kono; Claude B Sirlin; Aya Kamaya
Journal:  Radiographics       Date:  2019 May-Jun       Impact factor: 5.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.